Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer
-
Add time:07/16/2019 Source:sciencedirect.com
BackgroundPlasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. However, the relevance of plasma AR status in the context of cabazitaxel therapy is unknown.
We also recommend Trading Suppliers and Manufacturers of (aR)-2,2'-Dihydroxy-1,1'-binaphthalene-3,3'-dicarboxylic acid (cas 18531-92-5). Pls Click Website Link as below: cas 18531-92-5 suppliers
Prev:U-Pb, Rb-Sr and Ar-Ar systematics of the ungrouped achondrites Northwest Africa 6704 and Northwest Africa 6693
Next:Refined insight into 40Ar/39Ar progressive crushing technique from K–Cl–Ar correlations in fluid inclusions) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Formation of the Wulong gold deposit, Liaodong gold Province, NE China: Constraints from zircon U–Pb age, sericite Ar–Ar age, and H–O–S–He isotopes07/19/2019
- Simultaneous determination of ascorbic acid, dopamine and uric acid by a novel electrochemical sensor based on N2/Ar RF plasma assisted graphene nanosheets/graphene nanoribbons07/18/2019
- Refined insight into 40Ar/39Ar progressive crushing technique from K–Cl–Ar correlations in fluid inclusions07/17/2019
- U-Pb, Rb-Sr and Ar-Ar systematics of the ungrouped achondrites Northwest Africa 6704 and Northwest Africa 669307/15/2019
- Modeling and spectral simulation of formic acid dimer in Ar matrix using ONIOM calculations07/14/2019
